Association of African-American ethnic background with survival in men with metastatic prostate cancer
- PMID:11158191
- DOI: 10.1093/jnci/93.3.219
Association of African-American ethnic background with survival in men with metastatic prostate cancer
Abstract
Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and higher mortality than white men. It is not known whether the poorer survival of African-American men with prostate cancer reflects their later stage at diagnosis or differences in the basic biology of their disease. To evaluate this question, we examined outcomes of African-American and white men with metastatic prostate cancer in the context of a randomized clinical trial.
Methods: Southwest Oncology Group Study 8894 was a randomized phase III trial that compared orchiectomy with or without flutamide in men with metastatic prostate cancer. Using data from 288 African-American and 975 white men in the trial, we conducted a proportional hazards regression analysis to determine if ethnicity was an independent predictor of survival. All statistical tests were two-sided.
Results: African-American men were more likely than white men to have extensive disease and bone pain and had poorer performance status, younger age at study entry, higher Gleason score, and higher PSA levels. After adjustment for these prognostic variables, the hazard ratio (HR) for all-cause mortality for African-American men relative to white men was 1.23 (P: =.018). Further adjustment for initial quality-of-life assessments also resulted in higher HRs associated with African-American ethnicity relative to white ethnicity (HR = 1.39; P: =.007).
Conclusions: African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study. These data should give increased impetus for efforts to detect the disease early in African-American men and for the development of more effective therapies based on potential biologic differences in this ethnic group.
Comment in
- Re: Association of African-American ethnic background with survival in men with metastatic prostate cancer.Polednak AP.Polednak AP.J Natl Cancer Inst. 2001 Aug 1;93(15):1174-5. doi: 10.1093/jnci/93.15.1174.J Natl Cancer Inst. 2001.PMID:11481391No abstract available.
Similar articles
- Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D.Roach M 3rd, et al.J Urol. 2003 Jan;169(1):245-50. doi: 10.1016/S0022-5347(05)64078-5.J Urol. 2003.PMID:12478146
- Impact of race on survival in men with metastatic hormone-refractory prostate cancer.Halabi S, Small EJ, Vogelzang NJ, Barrier RC Jr, George SL, Gilligan TD.Halabi S, et al.Urology. 2004 Aug;64(2):212-7. doi: 10.1016/j.urology.2004.04.014.Urology. 2004.PMID:15302462
- Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL.Albain KS, et al.J Natl Cancer Inst. 2009 Jul 15;101(14):984-92. doi: 10.1093/jnci/djp175. Epub 2009 Jul 7.J Natl Cancer Inst. 2009.PMID:19584328Free PMC article.
- Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y.Evans S, et al.Int J Cancer. 2008 Jul 15;123(2):430-435. doi: 10.1002/ijc.23500.Int J Cancer. 2008.PMID:18452170Review.
- Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis.Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD.Sridhar G, et al.Am J Mens Health. 2010 Sep;4(3):189-206. doi: 10.1177/1557988309353934. Epub 2010 May 18.Am J Mens Health. 2010.PMID:20483872Review.
Cited by
- Analyzing Factors Enabling Prostate Cancer Screening Behaviors Among African American Males in the South Region Using the Andersen's Behavioral Model of Healthcare Services Utilization.Kim Y, Alhassan M.Kim Y, et al.J Prev (2022). 2023 Apr;44(2):253-266. doi: 10.1007/s10935-023-00722-6. Epub 2023 Jan 19.J Prev (2022). 2023.PMID:36653553
- Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Gong J, Kim DM, De Hoedt AM, Bhowmick N, Figlin R, Kim HL, Sandler H, Theodorescu D, Posadas E, Freedland SJ.Gong J, et al.J Clin Oncol. 2024 Jan 10;42(2):228-236. doi: 10.1200/JCO.23.00949. Epub 2023 Oct 27.J Clin Oncol. 2024.PMID:37890125Free PMC article.Review.
- Risk stratification in the hormonal treatment of patients with prostate cancer.Uhlman MA, Moul JW, Tang P, Stackhouse DA, Sun L.Uhlman MA, et al.Ther Adv Med Oncol. 2009 Sep;1(2):79-94. doi: 10.1177/1758834009340164.Ther Adv Med Oncol. 2009.PMID:21789114Free PMC article.
- A systematic review of the impact of pain on overall survival in patients with cancer.Zylla D, Steele G, Gupta P.Zylla D, et al.Support Care Cancer. 2017 May;25(5):1687-1698. doi: 10.1007/s00520-017-3614-y. Epub 2017 Feb 11.Support Care Cancer. 2017.PMID:28190159Review.
- Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Monaghan KG, Koprowski A, Mitrache N, Yang JJ, Rybicki BA.Nock NL, et al.Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45. doi: 10.1158/1055-9965.EPI-06-0736.Cancer Epidemiol Biomarkers Prev. 2007.PMID:17548691Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous